Fig. 4: Kaplan-Meier curves and subgroup analysis of PFS. | Nature Communications

Fig. 4: Kaplan-Meier curves and subgroup analysis of PFS.

From: Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial

Fig. 4

a Kaplan-Meier curves of PFS. The mPFS was 4.1 months (95% CI: 3.4–4.8). The 95% CIs for point estimates are shown in gray shading. Data are presented as median (95% CI). b Forest plot for the subgroup analysis of PFS. Univariate analysis of PFS revealed significant differences in gender. Data are presented as Hazard Ratio (95% CI). Source data are provided as a Source Data file. PFS progression free survival, mPFS median PFS.

Back to article page